Copyright Reports & Markets. All rights reserved.

Global Endothelin Antagonist Therapy Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Endothelin Antagonist Therapy
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Endothelin Antagonist Therapy by Type
    • 1.3.1 Overview: Global Endothelin Antagonist Therapy Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Endothelin Antagonist Therapy Consumption Value Market Share by Type in 2022
    • 1.3.3 Oral
    • 1.3.4 Parenteral
  • 1.4 Global Endothelin Antagonist Therapy Market by Application
    • 1.4.1 Overview: Global Endothelin Antagonist Therapy Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospitals
    • 1.4.3 Specialty Clinics
    • 1.4.4 Diagnostic Centers
    • 1.4.5 Others
  • 1.5 Global Endothelin Antagonist Therapy Market Size & Forecast
  • 1.6 Global Endothelin Antagonist Therapy Market Size and Forecast by Region
    • 1.6.1 Global Endothelin Antagonist Therapy Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Endothelin Antagonist Therapy Market Size by Region, (2018-2029)
    • 1.6.3 North America Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)
    • 1.6.6 South America Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Endothelin Antagonist Therapy Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Gilead Sciences
    • 2.1.1 Gilead Sciences Details
    • 2.1.2 Gilead Sciences Major Business
    • 2.1.3 Gilead Sciences Endothelin Antagonist Therapy Product and Solutions
    • 2.1.4 Gilead Sciences Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Gilead Sciences Recent Developments and Future Plans
  • 2.2 Sun Pharmaceutical Industries
    • 2.2.1 Sun Pharmaceutical Industries Details
    • 2.2.2 Sun Pharmaceutical Industries Major Business
    • 2.2.3 Sun Pharmaceutical Industries Endothelin Antagonist Therapy Product and Solutions
    • 2.2.4 Sun Pharmaceutical Industries Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
  • 2.3 Lupin
    • 2.3.1 Lupin Details
    • 2.3.2 Lupin Major Business
    • 2.3.3 Lupin Endothelin Antagonist Therapy Product and Solutions
    • 2.3.4 Lupin Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Lupin Recent Developments and Future Plans
  • 2.4 Zydus Group
    • 2.4.1 Zydus Group Details
    • 2.4.2 Zydus Group Major Business
    • 2.4.3 Zydus Group Endothelin Antagonist Therapy Product and Solutions
    • 2.4.4 Zydus Group Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Zydus Group Recent Developments and Future Plans
  • 2.5 Endo International
    • 2.5.1 Endo International Details
    • 2.5.2 Endo International Major Business
    • 2.5.3 Endo International Endothelin Antagonist Therapy Product and Solutions
    • 2.5.4 Endo International Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Endo International Recent Developments and Future Plans
  • 2.6 Mylan N.V
    • 2.6.1 Mylan N.V Details
    • 2.6.2 Mylan N.V Major Business
    • 2.6.3 Mylan N.V Endothelin Antagonist Therapy Product and Solutions
    • 2.6.4 Mylan N.V Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Mylan N.V Recent Developments and Future Plans
  • 2.7 Teva Pharmaceutical Industries
    • 2.7.1 Teva Pharmaceutical Industries Details
    • 2.7.2 Teva Pharmaceutical Industries Major Business
    • 2.7.3 Teva Pharmaceutical Industries Endothelin Antagonist Therapy Product and Solutions
    • 2.7.4 Teva Pharmaceutical Industries Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
  • 2.8 Sigmapharm Laboratories
    • 2.8.1 Sigmapharm Laboratories Details
    • 2.8.2 Sigmapharm Laboratories Major Business
    • 2.8.3 Sigmapharm Laboratories Endothelin Antagonist Therapy Product and Solutions
    • 2.8.4 Sigmapharm Laboratories Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Sigmapharm Laboratories Recent Developments and Future Plans
  • 2.9 Alembic Pharmaceuticals
    • 2.9.1 Alembic Pharmaceuticals Details
    • 2.9.2 Alembic Pharmaceuticals Major Business
    • 2.9.3 Alembic Pharmaceuticals Endothelin Antagonist Therapy Product and Solutions
    • 2.9.4 Alembic Pharmaceuticals Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Alembic Pharmaceuticals Recent Developments and Future Plans
  • 2.10 Hikma Pharmaceuticals
    • 2.10.1 Hikma Pharmaceuticals Details
    • 2.10.2 Hikma Pharmaceuticals Major Business
    • 2.10.3 Hikma Pharmaceuticals Endothelin Antagonist Therapy Product and Solutions
    • 2.10.4 Hikma Pharmaceuticals Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Hikma Pharmaceuticals Recent Developments and Future Plans
  • 2.11 Amneal Pharmaceuticals
    • 2.11.1 Amneal Pharmaceuticals Details
    • 2.11.2 Amneal Pharmaceuticals Major Business
    • 2.11.3 Amneal Pharmaceuticals Endothelin Antagonist Therapy Product and Solutions
    • 2.11.4 Amneal Pharmaceuticals Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Amneal Pharmaceuticals Recent Developments and Future Plans
  • 2.12 AstraZeneca
    • 2.12.1 AstraZeneca Details
    • 2.12.2 AstraZeneca Major Business
    • 2.12.3 AstraZeneca Endothelin Antagonist Therapy Product and Solutions
    • 2.12.4 AstraZeneca Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 AstraZeneca Recent Developments and Future Plans
  • 2.13 Johnsons & Johnsons Private limited
    • 2.13.1 Johnsons & Johnsons Private limited Details
    • 2.13.2 Johnsons & Johnsons Private limited Major Business
    • 2.13.3 Johnsons & Johnsons Private limited Endothelin Antagonist Therapy Product and Solutions
    • 2.13.4 Johnsons & Johnsons Private limited Endothelin Antagonist Therapy Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Johnsons & Johnsons Private limited Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Endothelin Antagonist Therapy Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Endothelin Antagonist Therapy by Company Revenue
    • 3.2.2 Top 3 Endothelin Antagonist Therapy Players Market Share in 2022
    • 3.2.3 Top 6 Endothelin Antagonist Therapy Players Market Share in 2022
  • 3.3 Endothelin Antagonist Therapy Market: Overall Company Footprint Analysis
    • 3.3.1 Endothelin Antagonist Therapy Market: Region Footprint
    • 3.3.2 Endothelin Antagonist Therapy Market: Company Product Type Footprint
    • 3.3.3 Endothelin Antagonist Therapy Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Endothelin Antagonist Therapy Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Endothelin Antagonist Therapy Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Endothelin Antagonist Therapy Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Endothelin Antagonist Therapy Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
  • 6.2 North America Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
  • 6.3 North America Endothelin Antagonist Therapy Market Size by Country
    • 6.3.1 North America Endothelin Antagonist Therapy Consumption Value by Country (2018-2029)
    • 6.3.2 United States Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
  • 7.2 Europe Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
  • 7.3 Europe Endothelin Antagonist Therapy Market Size by Country
    • 7.3.1 Europe Endothelin Antagonist Therapy Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 7.3.3 France Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Endothelin Antagonist Therapy Market Size by Region
    • 8.3.1 Asia-Pacific Endothelin Antagonist Therapy Consumption Value by Region (2018-2029)
    • 8.3.2 China Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 8.3.5 India Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
  • 9.2 South America Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
  • 9.3 South America Endothelin Antagonist Therapy Market Size by Country
    • 9.3.1 South America Endothelin Antagonist Therapy Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Endothelin Antagonist Therapy Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Endothelin Antagonist Therapy Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Endothelin Antagonist Therapy Market Size by Country
    • 10.3.1 Middle East & Africa Endothelin Antagonist Therapy Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Endothelin Antagonist Therapy Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Endothelin Antagonist Therapy Market Drivers
  • 11.2 Endothelin Antagonist Therapy Market Restraints
  • 11.3 Endothelin Antagonist Therapy Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Endothelin Antagonist Therapy Industry Chain
  • 12.2 Endothelin Antagonist Therapy Upstream Analysis
  • 12.3 Endothelin Antagonist Therapy Midstream Analysis
  • 12.4 Endothelin Antagonist Therapy Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Endothelin Antagonist Therapy market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    This report is a detailed and comprehensive analysis for global Endothelin Antagonist Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Endothelin Antagonist Therapy market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Endothelin Antagonist Therapy market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Endothelin Antagonist Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Endothelin Antagonist Therapy market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Endothelin Antagonist Therapy
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Endothelin Antagonist Therapy market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Sun Pharmaceutical Industries, Lupin, Zydus Group and Endo International, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Endothelin Antagonist Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Oral
    Parenteral
    Market segment by Application
    Hospitals
    Specialty Clinics
    Diagnostic Centers
    Others
    Market segment by players, this report covers
    Gilead Sciences
    Sun Pharmaceutical Industries
    Lupin
    Zydus Group
    Endo International
    Mylan N.V
    Teva Pharmaceutical Industries
    Sigmapharm Laboratories
    Alembic Pharmaceuticals
    Hikma Pharmaceuticals
    Amneal Pharmaceuticals
    AstraZeneca
    Johnsons & Johnsons Private limited
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Endothelin Antagonist Therapy product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Endothelin Antagonist Therapy, with revenue, gross margin and global market share of Endothelin Antagonist Therapy from 2018 to 2023.
    Chapter 3, the Endothelin Antagonist Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Endothelin Antagonist Therapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Endothelin Antagonist Therapy.
    Chapter 13, to describe Endothelin Antagonist Therapy research findings and conclusion.

    Buy now